Medicine and Dentistry
B Cell
38%
B Lymphocyte Receptor
8%
Biological Marker
16%
Biopsy
7%
Cancer
16%
Cas9
16%
CD20
12%
Cisplatin
16%
Clustered Regularly Interspaced Short Palindromic Repeat
33%
Combination Chemotherapy
5%
Copy Number Variation
5%
Cyclophosphamide
9%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
32%
Diagnosis
13%
Diffuse Large B-Cell Lymphoma
96%
Diffuse Large B-Cell Lymphoma Cell Line
5%
DNA Damage Response
16%
Doxorubicin
8%
Drug Effect
5%
Exome Sequencing
5%
Follicular Lymphoma
5%
Gene Expression
7%
Germinal Center
6%
Immunotherapy
5%
International Prognostic Index
17%
Malignant Neoplasm
10%
Mediator
16%
microRNA
21%
microRNA 155
35%
Multiple Myeloma
16%
Neoplasm
21%
Non-Hodgkin Lymphoma
5%
Personalized Medicine
7%
Prednisone
6%
Principal Component Analysis
5%
Programmed Cell Death
16%
Proportional Hazards Model
5%
Protein Tyrosine Kinase
16%
Rituximab
25%
Symptomatic Treatment
5%
Targeted Therapy
5%
Vincristine
24%
Keyphrases
17-AAG
13%
B-cell Linker
16%
Bendamustine
16%
Branching Evolution
5%
Bruton's Tyrosine Kinase
16%
Chlorambucil
5%
Cisplatin Response
16%
CRISPR Interference (CRISPRi)
16%
CRISPR-Cas9 Knockout
16%
ERCC6
7%
High-grade non-Hodgkin Lymphoma
5%
Hsp90 Inhibitor
16%
In Situ Lymphoma
5%
Individual Evaluation
5%
Knockout Screen
16%
Linker Peptide
16%
Long-term Remission
11%
Molecular Classification
16%
Neuropathy Disability Score
12%
Notch3
16%
Platinum Drugs
5%
RELAP
5%
Relapsed Lymphoma
5%
Relapsed Tumor
5%
Transformed Lymphoma
5%
Tumor DNA
5%
Vincristine-induced Neuropathy
16%
WEE1
5%
Immunology and Microbiology
B Cell
100%
B Cell Lymphoma Cell
5%
B-Cell Receptor
7%
CD20
6%
Cell Death
16%
Cell Line
6%
Clustered Regularly Interspaced Short Palindromic Repeat
20%
CRISPR/Cas9
16%
CXCR4
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
37%
Diffuse Large B-Cell Lymphoma Cell Line
8%
Germinal Center
6%
Mediator
16%
Rituximab
37%
